Maciej Hilczer1, Joanna Smyczynska, Andrzej Lewinski. 1. Department of Endocrinology and Metabolic Diseases, Medical University of Lodz, Polish Mother's Memorial Hospital - Research Institute, Lodz, Poland.
Abstract
OBJECTIVE: The diagnosis of growth hormone (GH) deficiency (GHD) is routinely based on the results of two stimulating tests performed with different stimuli. Arbitrarily established, equal cutoff levels for the tests with different pharmacological stimuli, as well as a relatively high incidence of falsely decreased (FD) response in the tests have been reported. Falsely decreased GH response in one of the two performed tests does not exclude FD response in the second one, so, it seems very important to assess the incidence of FD response in both GH stimulating tests. SUBJECTS AND METHODS: The analysis comprised the results of two GH stimulating tests (the 1st one with clonidine, the 2nd one with either insulin or glucagon) performed in 780 short children. RESULTS: The mean GH peak in the test with clonidine was significantly higher than that in both other tests (p<0.01). The rate of decreased GH secretion was 48.7 % in the test with clonidine, 80.5 % in the test with insulin and 81.5 % in the test with glucagon. Similar frequency of normal and subnormal test results was obtained for the cut-off value for the tests with insulin and with glucagon at the level of 6.4 ng/ml. The correlation between the results of the two tests as performed in particular patients was weak (r=0.27; p<0.05). Following cases of test results were found: 1. both results normal (1st NT, 2nd NT) in 117 patients (15.0 %), 2. 1st result normal, while the 2nd one falsely decreased (1st NT, 2nd FD) in 283 (36.3 %), 3. reverse situation (1st FD, 2nd NT) in 62 (7.9 %), 4. both results decreased in 318 (40.8 %), either truly (1st TD, 2nd TD) or falsely (1st FD, 2nd FD) - with unknown incidence. The following incidences (probabilities - P) result from the above data: A. P(1st NT, 2nd NT) = P(1st NT) intersection P(2nd NT) = 0.150; B. P(1st NT, 2nd FD) = P(1st NT) intersection P(2nd FD) = 0.363; C. P(1st FD, 2nd NT) = P(1st FD) intersection P(2nd NT) = 0.079. The expression (B intersection C)/A was calculated by transforming the right side of the equations: (B x C)/A = 0.192. Thus, 19.2 %, out of all 780 patients, i.e., 150 children (47.2 % of 318 patients, assessed as GH-deficient), could have both test results FD. CONCLUSIONS: The observed differences in GH response to particular pharmacological stimuli, as well as the high incidence of falsely decreased GH response in the two stimulating tests, should be taken into account in qualifying short children to GH therapy.
OBJECTIVE: The diagnosis of growth hormone (GH) deficiency (GHD) is routinely based on the results of two stimulating tests performed with different stimuli. Arbitrarily established, equal cutoff levels for the tests with different pharmacological stimuli, as well as a relatively high incidence of falsely decreased (FD) response in the tests have been reported. Falsely decreased GH response in one of the two performed tests does not exclude FD response in the second one, so, it seems very important to assess the incidence of FD response in both GH stimulating tests. SUBJECTS AND METHODS: The analysis comprised the results of two GH stimulating tests (the 1st one with clonidine, the 2nd one with either insulin or glucagon) performed in 780 short children. RESULTS: The mean GH peak in the test with clonidine was significantly higher than that in both other tests (p<0.01). The rate of decreased GH secretion was 48.7 % in the test with clonidine, 80.5 % in the test with insulin and 81.5 % in the test with glucagon. Similar frequency of normal and subnormal test results was obtained for the cut-off value for the tests with insulin and with glucagon at the level of 6.4 ng/ml. The correlation between the results of the two tests as performed in particular patients was weak (r=0.27; p<0.05). Following cases of test results were found: 1. both results normal (1st NT, 2nd NT) in 117 patients (15.0 %), 2. 1st result normal, while the 2nd one falsely decreased (1st NT, 2nd FD) in 283 (36.3 %), 3. reverse situation (1st FD, 2nd NT) in 62 (7.9 %), 4. both results decreased in 318 (40.8 %), either truly (1st TD, 2nd TD) or falsely (1st FD, 2nd FD) - with unknown incidence. The following incidences (probabilities - P) result from the above data: A. P(1st NT, 2nd NT) = P(1st NT) intersection P(2nd NT) = 0.150; B. P(1st NT, 2nd FD) = P(1st NT) intersection P(2nd FD) = 0.363; C. P(1st FD, 2nd NT) = P(1st FD) intersection P(2nd NT) = 0.079. The expression (B intersection C)/A was calculated by transforming the right side of the equations: (B x C)/A = 0.192. Thus, 19.2 %, out of all 780 patients, i.e., 150 children (47.2 % of 318 patients, assessed as GH-deficient), could have both test results FD. CONCLUSIONS: The observed differences in GH response to particular pharmacological stimuli, as well as the high incidence of falsely decreased GH response in the two stimulating tests, should be taken into account in qualifying short children to GH therapy.
Authors: Camilia Kamoun; Colin Patrick Hawkes; Hareesh Gunturi; Andrew Dauber; Joel N Hirschhorn; Adda Grimberg Journal: Horm Res Paediatr Date: 2021-10-18 Impact factor: 4.275
Authors: Maria A Kalina; Barbara Kalina-Faska; Katarzyna Gruszczyńska; Jan Baron; Ewa Małecka-Tendera Journal: Childs Nerv Syst Date: 2011-09-21 Impact factor: 1.475
Authors: João Soares Felício; Luísa Corrêa Janaú; Marcelle Alves Moraes; Nathalie Abdallah Zahalan; Fabrício de Souza Resende; Manuela Nascimento de Lemos; Norberto Jorge Kzan de Souza Neto; Isabela Imbelloni Farias de Franco; Loyane Tamyres Costa Leitão; Lilian de Souza d'Albuquerque Silva; Maria Clara Neres Iunes de Oliveira; Angélica Leite de Alcântara; Ana Carolina Contente Braga de Souza; Wanderson Maia da Silva; Márcia Costa Dos Santos; Natércia Neves Marques de Queiroz; Lorena Vilhena de Moraes; Antônio Bentes de Figueiredo; Ana Luiza Prieto Farinassi; Luciana Marques da Costa Farias; Danielle Dias da Silva; Karem Miléo Felício; João Felício Abrahão Neto Journal: Front Endocrinol (Lausanne) Date: 2019-09-19 Impact factor: 5.555
Authors: Alessandro Cattoni; Silvia Molinari; Francesco Medici; Paola De Lorenzo; Maria Grazia Valsecchi; Nicoletta Masera; Marta Adavastro; Andrea Biondi Journal: Front Endocrinol (Lausanne) Date: 2020-12-09 Impact factor: 5.555
Authors: Ju Young Yoon; Chong Kun Cheon; Jung Hyun Lee; Min Jung Kwak; Hyun-Ji Kim; Ye Jin Kim; Jeong Eun Lee; Woo Yeong Chung; Jeongyun Kim; Jae-Ho Yoo Journal: Ann Pediatr Endocrinol Metab Date: 2022-01-17